Nanoform Q2 and H1 2022 report: Strong momentum continues
Company Announcement Nanoform Finland Plc August 25, 2022 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Q2 and H1 2022 report: Strong momentum continues Capacity expansion continues according to plan, strong project intake from new and repeat customers, positive outcome from AstraZeneca’s technology evaluation, while the revenue grew by 100%, the number of employees by 35%, whereas the total operating cost growth was kept to 29% in H1/2022. Productivity gains and economies of scale will enable continued slower growth in costs while expanding our manufacturing